Enterome

Executive Summary

Enterome is a Paris-based clinical-stage biopharmaceutical company leveraging its gut microbiome decoding platform to develop novel immunomodulatory cancer therapies. Founded in 2012, the company's core technology identifies OncoMimics™ peptides that mimic tumor antigens, eliciting potent and durable T-cell responses. Enterome's lead program, EO-2401, is a combination of three OncoMimics targeting glioblastoma, currently in Phase 2 trials. The company also has a diagnostics division focused on microbiome-based biomarkers. With a unique approach bridging microbiome science and immuno-oncology, Enterome has the potential to address high unmet needs in difficult-to-treat cancers, though it remains early-stage and capital-dependent.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for EO-2401 in glioblastoma40% success
• TBDPartnership or licensing deal for OncoMimics platform50% success
• H1 2027New clinical trial initiation for additional OncoMimics candidates60% success